Lorenzoni Paulo José, Kay Cláudia Suemi Kamoi, Ducci Renata Dal-Prá, Fustes Otto Jesus Hernandez, Werneck Lineu Cesar, Scola Rosana Herminia
Departamento de Clínica Médica, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Arq Neuropsiquiatr. 2020 Mar;78(3):179-181. doi: 10.1590/0004-282X20190189. Epub 2020 Mar 16.
Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its "pioneering trials" to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these "pioneering trials", this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.
目前，溴吡斯的明是全球用于治疗重症肌无力（MG）患者的一种不可或缺的抗胆碱酯酶药物。然而，溴吡斯的明在其治疗一系列MG患者的“开创性试验”中并不成功。在溴吡斯的明对MG治疗变得有用、安全且不可或缺之前，有一些重要的历史里程碑。在这些“开创性试验”进行70年后，本文回顾了与之相关的一些历史方面，以及其他使用溴吡斯的明治疗MG患者的初步试验。
